Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study assessing if people with MS on and off disease modification treatments) (DMT) develop and maintain adequate adaptive immune response after the completed course of Covid-19 vaccination compared to healthy controls

Next Previous
Trial Profile

Study assessing if people with MS on and off disease modification treatments) (DMT) develop and maintain adequate adaptive immune response after the completed course of Covid-19 vaccination compared to healthy controls

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Interferon (Primary) ; Natalizumab (Primary) ; Ocrelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics

Most Recent Events

  • 20 Dec 2022 New trial record
  • 28 Oct 2022 Results presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top